Drugdiscovery >> Drugs >> News
2789
Views
GSK recalls a plenty of its anti-adiposis drug - drugdiscovery.com
GSK recalls a plenty of its anti-adiposis drug - drugdiscovery.com


GlaxoSmithKline recalled several of its weight loss drugs. Tha company says they could not make sure that some packages of the product were not tampered with contain product that is not authentic Alli.
Read More >>


Tags: package, tampered, GSK, weight loss - March 30, 2014
Related Articles
4826
Views
Metformin,  anti-aging effects? Metformin, anti-aging effects?
Recently published research has shown that metformin, the diabetes drug, extends the lifespan of mice fed the drug. The drug simulated many of the effects of caloric restriction but high-doses resulte Read More >>

Tags: Metformin, diabetes drug, anti-aging, effect, mice

3199
Views
NICE recommends Iluvien as an option for patients with chronic diabetic macular oedema NICE recommends Iluvien as an option for patients with chronic diabetic macular oedema
Iluvien (fluocinolone acetonide intravitreal implant) is a corticosteroid with anti-inflammatory and anti-vascular endothelial growth factor (anti-VEGF) properties. The treatment is recommended when Read More >>

Tags: Iluvien, diabetic macular edema, chronic, anti-VEGF, anti-inflammatory, corticosteroid, Alimera

3851
Views
Orlistat might cause kidney stones Orlistat might cause kidney stones
The results of an animal study suggest that one of the side effects of an anti-obesity drug orlistat might be the increased risk of kidney stones. Read More >>

Tags: orlistat, anti-obesity drug, risk, side effects, kidney stones, animal study

1596
Views
Anti-psychotics & Insulin Resistance Anti-psychotics & Insulin Resistance
Several anti-psychotics have been shown to induce insulin resistance in healthy individuals. Read More >>

Tags: Abilify, Aripiprazole, Zyprexa, Olanzapine

4697
Views
A new indication for Lucentis in EU A new indication for Lucentis in EU
The European Commission has granted Novartis a new indication for Lucentis® (ranibizumab) to treat patients with visual impairment due to myopic choroidal neovascularization (CNV). Read More >>

Tags: Lucentis, Novartis, Anti-VEGF Treatment, Myopic choroidal neovascularization

3036
Views
Combining tofacitinib with DMARDs beneficial for patients with active rheumatoid arthritis Combining tofacitinib with DMARDs beneficial for patients with active rheumatoid arthritis
According to a recent study, tofacitinib, in addition to disease-modifying anti-rheumatic drugs (DMARDs),showed safe and effective in improving symptoms in patients with active rheumatoid arthritis Read More >>

Tags: rheumatoid arthritis, tofacitinib, Janus kinase inhibitor, anti-rheumatic drugs

3223
Views
The FDA warns about Ortiga supplement The FDA warns about Ortiga supplement
Ortiga is unapproved product promoted for a range of health conditions and sold on multiple websites. FDA analysis confirmed that Ortiga contains diclofenac, a prescription non-steroidal anti-inflamma Read More >>

Tags: ortiga, ortiga supplement, FDA warning, diclofenac, non-steroidal anti-inflammatory

6148
Views
New Drug Application for Delcath's drug rejected New Drug Application for Delcath's drug rejected
The FDA has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for Delcath Systems’ drug MelblezTM Kit, for the treatment of patients with unresectable ocular melanoma Read More >>

Tags: new drug application, NDA, Delcath, ocular melanoma, drug, Melblez, melphalan

8182
Views
SOLIAIR™: New Respiratory Diseases Drug Discovery! SOLIAIR™: New Respiratory Diseases Drug Discovery!
SOLIAIR™ is a food supplement which has reported beneficial impact. Patients taking SOLIAIR™ reported a decrease in seasonal infections of the respiratory tract. The SOLIAIR™ is free of side eff Read More >>

Tags: Drug Development,Drug Discovery,Medicine Development,COPD Treatment,Asthma Solution,Bronchitis Therapy,Respiratory Diseases,Lung Infections,Breathing Disorders,healthcare investment,Drug Innovation,

13093
Views
Orphan Drug Designation for Hemophilia B drug ALN-AT3 Orphan Drug Designation for Hemophilia B drug ALN-AT3
FDA has approved an Orphan Drug Designation to Alnylam Pharmaceuticals’ drug ALN-AT3 for the treatment of hemophilia B. ALN AT3 is subcutaneously administered RNAi therapeutic which targets antith Read More >>

Tags: orphan drug, ALN-AT3, hemophilia B, antithrombin, RNAi,Alnylam

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013